FILE - In this July 20, 2006 file photo, a woman smokes a cigarette during a break from work in downtown Chicago. New research published in the New England Journal of Medicine's issue coming out Thursday, Jan. 24, 2013, finds that women who smoke today have a much greater risk of dying from lung cancer than they did decades ago compared to those who never smoked. That is partly because they are starting younger and smoking more than women used to. (AP Photo/Julio Cortez, File)
Novo Nordisk says FDA rejects insulin drugs
Published: 11:26:27 PM, Sun 10 February 2013 UTC
NEW YORK (AP) — Novo Nordisk AS says the Food and Drug Administration rejected its applications for approval of once-per-day insulin drugs to treat diabetes.
The Danish drugmaker says it received a "complete response letter" from the FDA regarding its applications for approval of Tresiba and Ryzodeg, or insulin degludec, on Friday. Such a letter indicates the agency determined the application cannot be approved in its current form.
In November, panel of federal health advisers recommended that the government approve degludec. The FDA is not required to follow the group's advice, but it often does.
Tresiba contains long-acting insulin, and Ryzodeg contains both long- and short-acting insulins.
Diabetics either do not produce enough of the hormone insulin or do not use it efficiently, allowing excess sugar, or glucose, to accumulate in the blood.
Tags:
ap, novo nordisk, health, drug administration, panel, diabetes, nutrition, friday, application, current form, insulin, diabetes mellitus, group, food, new york, growth hormone, approval, agency, glucose, applications, insulin drugs, ryzodeg, diabetics, danish drugmaker, fda rejects insulin, once-per-day insulin drugs, long-acting insulin, insulin degludec, federal health advisers, complete response letter, hormone insulin, short-acting insulins, excess sugar, tresiba, hormone
